序号

药物名称

在研公司

目前较高研究阶段

1

DKF-313

Dong Kook Pharmaceutical Co Ltd

Phase 1 Clinical

2

insulin lispro biosimilar

Sanofi

Phase 3 Clinical

3

dupilumab

Regeneron Pharmaceuticals Inc; Sanofi

Phase 3 Clinical

4

ibrutinib

Janssen Biotech Inc; Johnson & Johnson; Pharmacyclics Inc

Launched

5

MEDI-6469 + tremelimumab (solid tumor)

MedImmune LLC

Phase 1 Clinical

6

diphenylcyclopropenone (gel)

RXi Pharmaceuticals Corp

Phase 2 Clinical

7

AKP-11

Akaal Pharma Pty Ltd

Phase 1 Clinical

8

SAR-408701

Sanofi

Phase 2 Clinical

9

durvalumab

AstraZeneca plc; MedImmune LLC

Phase 3 Clinical

10

namilumab

Takeda Pharmaceuticals International GmbH

Phase 2 Clinical

11

GZ-402666

Genzyme Corp

Phase 3 Clinical

12

moxifloxacin hydrochloride + triamcinolone acetonide (LessDrop combination, ophthalmic formulation)

Imprimis Pharmaceuticals Inc

Clinical

13

prednisolone acetate + moxifloxacin hydrochloride (eye drop formulation)

Imprimis Pharmaceuticals Inc

Clinical

14

demcizumab

Celgene Corp; OncoMed Pharmaceuticals Inc

Phase 2 Clinical

15

nivolumab

Bristol-Myers Squibb Co; Medarex Inc; Ono Pharmaceutical Co Ltd

Launched

16

BBI-5000

Brickell Biotech Inc

Phase 1 Clinical

17

ASP-6858

Astellas Pharma Inc

Phase 1 Clinical

18

ASP-5094

Astellas Pharma Inc

Phase 1 Clinical

19

BBI-4000

Brickel

厚朴方舟2012年进入海外医疗领域，总部位于北京，建立了由全球权威医学专家组成的美日名医集团，初个拥有日本政府官方颁发的海外医疗资格的企业。如果您有海外就医的需要，请拨打免费热线400-086-8008进行咨询！

本文由厚朴方舟编译，版权归厚朴方舟所有，转载或引用本网版权所有之内容须注明"转自厚朴方舟官网（www.hopenoah.com）"字样，对不遵守本声明或其他违法、恶意使用本网内容者，本网保留追究其法律责任的权利。

上一篇：中国患者如何快速获得日本和美国的丙肝新药 下一篇：乳腺癌患者的福音—晚期乳癌的新药IBRANCE获批